Could Washington be the next state to ease regulations on psychedelic use? It is what state Sen. Jesse Salomon hopes to do this session with his newly proposed bill.
SB 5660 would legalise the use of psilocybin, a compound found in magic mushrooms, for therapeutic purposes, potentially providing a valuable mental health resource, according to Salomon.
“It has shown a lot of promise through FDA-approved John Hopkins University studies and many other studies in terms of addiction recovery, and healing depression and anxiety,” - Sen. Jesse Salomon.
“The first study was people with terminal illness who couldn’t get over the fact that they were going to die, and had tried all other mental health avenues to deal with that anxiety and depression,” he continued. “They were able to ease their symptoms through this process.”
Other research on addiction treatment have showed consistent beneficial results. In 2016, ten patients suffering from alcoholism were given psilocybin and saw a 50% drop in their alcohol use after ten weeks. In a separate 2014 study from Johns Hopkins University, 15 smokers were given psilocybin treatments, and after six months, 12 of the 15 had quit smoking completely.
Sen. Salomon also sees potential benefits for those who have suffered from mental illness as a result of the pandemic.
“This is the mental health fix that we’ve been looking for,” he posited. “It is something that works for a lot of people who have not been successful in all other medical and mental health treatments, and with COVID driving up mental health problems, this is actually exactly what we need to give people an additional avenue to heal.”
He further adds that "this is not the same as marijuana legalisation," explaining that in order to obtain psilocybin treatments, patients would still need to consult with service centres to discuss their medical concerns and mental health background.
“I have no intention in this bill to just have people go and buy it from a store,” he clarified. “This is integrated with mental health or self development.”
About CUBE PSYTECH INC.
Cube Psytech Corporation. is a Canadian bio-pharmaceutical and biotechnology company focused on the use of psilocybin to improve health issues such as mental illness, PTSD, addiction disorders, cancer, and depression. The company is comprised of a best of class sciences and executive leadership team with access to bio-pharmaceutical patents.
investors@cubepsytech.com
All Rights Reserved | Cube Psytech